Search Results - "Teptsova, T."

Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system by Teptsova, T. S., Musina, N. Z., Omelyanovsky, V. V.

“…Introduction. Presently, the willingness-to-pay threshold (cost-effectiveness threshold, incremental cost-effectiveness ratio) is used as one of the…”
Get full text

Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients by Fedina, E. G., Perova, K. A., Teptsova, T. S., Shchurov, D. S.

“…The study aims to estimate the MitraClip system’s cost-effectiveness compared with optimal medical therapy in adult patients with inoperable mitral…”
Get full text

Real-world data: principles of use in decision making and in health technology assessment by Omelyanovskiy, V. V., Gorkavenko, F. V., Ignatyeva, N. V., Mukhortova, P. A., Ryzhova, O. R., Teptsova, T. S., Kingshott, A. A., Kondratyeva, B. B.

“…The use of real-world data (RWD) and real-world evidence (RWE) in process of improving public health, their assessment, and use in decision making is a…”
Get full text

Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions by Hachatryan, G. R., Teptsova, T. S., Lemeshko, V. A., Musina, N. Z.

“…The aim is to analyze the medical records of patients with malignant lymphoproliferative diseases (LPD) in the Russian Federation in 2016- 2017. Materials and…”
Get full text

Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies by Teptsova, T. S., Bezdenezhnyh, T. P., Fedyaeva, V. K., Musina, N. Z, Hachatryan, G. R., Tarasov, V. V.

“…The aim was to develop a methodology for determining the willingness to pay threshold (WTPT) and its upper limit value within the Russian health care system…”
Get full text

PCN165 Incremental Cost-Effectiveness Ratio Values of the Anticancer Drugs Approved and Rejected for the Russian VITAL and Essential Drugs LIST in 2018 by Teptsova, T., Perova, K., Khachatryan, G., Omelyanovskiy, V., Agabekyan, S., Chetverikova, O., Shemyakova, O.

Get full text

Assessing the Relevance of Molecular Genetic Testing for Mutations in BRCA Genes of Patients with Ovarian and Breast Cancer by Lemeshko, V. A., Teptsova, T. S., Ratushnyak, S. S., Musina, N. Z.

“…Genetic predisposition is one of the main risk factors for developing breast cancer (BC) and ovarian cancer (OC). We conducted an analysis of the epidemiology…”
Get full text

Early Economic Evaluation of The New Atypical Antipsychotic by Musina, N, Vaskova, L, Omelyanovskiy, VV, Lemeshko, V, Teptsova, T

“…OBJECTIVES: To assess the economic viability of the new atypical antipsychotic and to establish what price is required for an economically viable drug. In this…”
Get full text

PMH30 - Early Economic Evaluation of The New Atypical Antipsychotic by Musina, N, Vaskova, L, Omelyanovskiy, VV, Lemeshko, V, Teptsova, T

Get full text

PCN270 AVAILABILITY OF EARLY PREVENTION AND TARGETED THERAPY FOR BRCA-ASSOSIATED PATIENTS WITH BREAST AND/OR OVARIAN CANCER by Lemeshko, V., Teptsova, T., Ratushnyak, S., Musina, N.Z.

Get full text